Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ARMP Armata Pharmaceuticals Inc

0.13 (3.30%)
Mar 01 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 13,095
Bid Price
Ask Price
News -
Day High 4.21


52 Week Range


Day Low 3.92
Company Name Stock Ticker Symbol Market Type
Armata Pharmaceuticals Inc ARMP AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.13 3.30% 4.07 20:00:00
Open Price Low Price High Price Close Price Prev Close
4.02 3.92 4.21 4.07 3.94
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
346 13,095 $ 4.05 $ 53,090 - 1.0701 - 5.2565
Last Trade Time Type Quantity Stock Price Currency
20:00:00 313 $ 4.07 USD

Armata Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 147.12M - - - -398.65
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Armata Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ARMP Message Board. Create One! See More Posts on ARMP Message Board See More Message Board Posts

Historical ARMP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.834.382.823.6728,6461.2443.82%
1 Month3.854.382.75723.5517,5310.225.71%
3 Months2.704.382.223.3919,9351.3750.74%
6 Months3.564.381.902.9619,6140.5114.33%
1 Year2.645.25651.07012.5955,4751.4354.17%
3 Years5.526.490.83113.1529,063-1.45-26.27%
5 Years4.9010.480.83113.7139,051-0.83-16.94%

Armata Pharmaceuticals Description

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Your Recent History

Delayed Upgrade Clock